Thursday, February 23, 2017 11:26:27 AM
I like the Google analogy. Pro-140 is disruptive and a couple steps away so we are just another Biotech play in the grind of the P3 process too many. Early adopters are the visionaries that make big $'s if they get it right.
Pro-140 is a calculated risk that has ALL major catalysts in play. With every catalyst that is cleared the risk will diminish. The unknown is will Pro-140 run the table on these catalysts or will we hit a wall at some point in the process. The Billion $ question is at what point will BP be convinced enough to take Pro-140 out. My belief is we have to make it to overwhelmingly positive interim data in reference to P3 Mono Trial-that is for a major return...10 bagger plus. Anything sooner is substantially less. Mono is what BP is really interested in. As Pears said a successful Adjunct P3 is the first bridge that must be crossed. The good news is the P3 Mono is in full tilt recruiting so they are being conducted simultaneously. My focus is on the data on both P3's which will tell us if Pro-140 is an unmarketable toothbrush or a Google. The data to this point heavilly favors a Google scenario.
Pro-140 is a calculated risk that has ALL major catalysts in play. With every catalyst that is cleared the risk will diminish. The unknown is will Pro-140 run the table on these catalysts or will we hit a wall at some point in the process. The Billion $ question is at what point will BP be convinced enough to take Pro-140 out. My belief is we have to make it to overwhelmingly positive interim data in reference to P3 Mono Trial-that is for a major return...10 bagger plus. Anything sooner is substantially less. Mono is what BP is really interested in. As Pears said a successful Adjunct P3 is the first bridge that must be crossed. The good news is the P3 Mono is in full tilt recruiting so they are being conducted simultaneously. My focus is on the data on both P3's which will tell us if Pro-140 is an unmarketable toothbrush or a Google. The data to this point heavilly favors a Google scenario.
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
